In neurodegenerative diseases such as AD and PD, mGluR5 antagonists, including MPEP and CTEP, have shown potential to reduce synaptic dysfunction, excitotoxicity, and neuroinflammation [10]. This evidence concerns the gene GRM5 and Parkinson disease.